Krystal Biotech Hits New 52-Week High of $361.74, Up 103.55% Year-to-Date

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 361.74 on June 25, 2026. This achievement underscores the company's robust performance over the past year, with a remarkable increase of 103.55%, significantly outpacing the S&P 500's growth of 20.77% during the same period. The company's market capitalization stands at USD 7,173 million, reflecting its position within the small-cap segment. Krystal Biotech's price-to-earnings (P/E) ratio is currently at 35.00, indicating investor sentiment towards its earnings potential. Additionally, the company maintains a return on equity of 16.80%, showcasing effective management of shareholder equity. Despite the absence of dividends, the company’s financial health is further illustrated by a debt-to-equity ratio of -0.68, suggesting a strong balance sheet. The price-to-book ratio of 5.88 indicates how the market values the company's assets relative to its stock price. Overall, Krystal Biotech's recent performance highlights its upward trajectory in the competitive biotechnology landscape.